SCHEMBL6370265

SCHEMBL6370265

[PbH2].c1ccc(Nc2ncccn2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.61
MAPT P10636 3/20 0.61
MAPK1 P28482 3/20 0.61
CDK1 P06493 3/20 0.61
PRKCD Q05655 2/20 0.61
PDPK1 O15530 2/20 0.61
LYN P07948 2/20 0.61
FGFR1 P11362 2/20 0.61
FGFR3 P22607 2/20 0.61
RPS6KB1 P23443 2/20 0.61
CDK2 P24941 2/20 0.61
MARK3 P27448 2/20 0.61
BLK P51451 2/20 0.61
RPS6KA3 P51812 2/20 0.61
ERBB4 Q15303 2/20 0.61
MARK2 Q7KZI7 2/20 0.61
PLK3 Q9H4B4 2/20 0.61
CHEK1 O14757 1/20 0.61
IKBKB O14920 1/20 0.61
NPC1 O15118 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15968669 0.97 AURKA (0.63) AURKAMAPTMAPK1CDK1PRKCD
SCHEMBL911 0.97 AURKA (0.63) AURKAMAPTMAPK1CDK1PRKCD
Hydrochloric Acid SCHEMBL6820971 0.95 MAPK1 (0.61) AURKAMAPTMAPK1CDK1PRKCD
Ammonia Solution, Strong SCHEMBL28789700 0.95 MAPT (0.61) AURKAMAPTMAPK1CDK1PRKCD
Pyrimidine SCHEMBL27837500 0.87 MAPT (0.53) AURKAMAPTMAPK1CDK1PRKCD
SCHEMBL29484614 0.85 MAPT (0.52) AURKAMAPTMAPK1CDK1PRKCD
SCHEMBL27835195 0.84 PRKCD (0.50) AURKAMAPTMAPK1CDK1PRKCD
Pyrimethanil SCHEMBL1467035 0.80 SMN1; SMN2 (0.61) AURKAMAPTMAPK1CDK1PRKCD
SCHEMBL5823445 0.80 RAD52 (0.48) AURKAMAPTMAPK1CDK1PRKCD
SCHEMBL27753867 0.79 AURKA (0.46) AURKAMAPTMAPK1CDK1PRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009849-A1 Pyridopyrimidine kinase inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2005-01-13 US disclosed
WO-2004063195-A1 PYRIDOPYRIMIDINE KINASE INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009849-A1 Pyridopyrimidine kinase inhibitors MAP3K1, MAP3K19, MAP3K20 AURKA 52/4885MAPT 2735/4885MAPK1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.